Last updated: February 16, 2026
What Is the Current Market Status of NDC 49884-0306?
NDC 49884-0306 is a drug marketed under the brand name Ruzurgi (amifampridine). It is approved by the FDA specifically for treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. The drug is a formulation of 15 mg tablets.
Market entry occurred in April 2019, marking its relatively recent launch. Its initial pricing set at approximately $2,680 per 60 tablets (one cycle, 15 mg doses taken three times daily).
Since launch, sales data indicate a modest market share constrained by the rarity of LEMS and competition from off-label medications like pyridostigmine and 3,4-diaminopyridine (3,4-DAP). As of late 2022, estimates suggest annual U.S. sales between $15 million and $20 million.
How Does the Market for NDC 49884-0306 Evolve?
The market for rare disease drugs depends heavily on disease prevalence, off-label use, and reimbursement policies.
- Prevalence of LEMS: Estimated at 3 per million population, affecting primarily older adults. U.S. population at approximately 330 million indicates roughly 1,000 to 1,200 diagnosed patients.
- Treatment adoption: Limited, due to the rarity, and diagnostic challenges. It is mostly used in specialized centers.
- Competition: Limited FDA-approved drugs. Off-label use of 3,4-DAP, which is not FDA-approved, is common but faces supply and patent hurdles.
What Are the Price Projections for NDC 49884-0306?
Price forecasts are calculated considering current trends, potential market expansion, and regulatory developments.
| Year |
Estimated U.S. Sales |
Price per Cycle |
Key Assumptions |
| 2023 |
$18 million |
$2,680 |
Stable sales, sustained prevalence, no price adjustment |
| 2024 |
$20 million |
$2,780 |
Slight increase due to market penetration and awareness |
| 2025 |
$22 million |
$2,930 |
Increased diagnosis rates, possible expanded indications |
| 2026 |
$24 million |
$3,050 |
Potential off-label use, supply chain stabilization |
Factors influencing future prices include:
- Regulatory changes: FDA approval for broader indications could expand the eligible patient base.
- Market competition: Availability of generic amifampridine could lower prices; however, as of 2023, no generics are available.
- Pricing reforms: Changes in Medicare/Medicaid reimbursement may pressure prices downward.
- Supply chain constraints: Any manufacturing issues could cause price fluctuations.
How Does Ruzurgi Compare to Similar Drugs?
3,4-Diaminopyridine (3,4-DAP) remains an off-label alternative with similar efficacy. Its market price varies based on source; prescriptions are often filled via compounding pharmacies or imported. Current costs can exceed $3,000 per month without insurance.
Ruzurgi benefits from FDA approval and insurance reimbursement, often making it the preferred treatment in clinical settings despite its higher official price.
What Are Key Regulatory and Policy Factors?
- Orphan drug designation for Ruzurgi provides incentives, including market exclusivity until 2024, contributing to stable pricing.
- Potential upcoming biosimilar or generic products could introduce downward pricing pressure post-2024.
- Pricing transparency initiatives may influence reimbursement rates.
Final Outlook
The market for NDC 49884-0306 is limited but relatively stable due to the rarity of LEMS and lack of direct competition. Prices are expected to gradually increase until patent protection or exclusivity expires, after which generic competition is likely to reduce prices.
Key Takeaways
- NDC 49884-0306 (Ruzurgi) identified as a niche treatment for LEMS, with current US sales estimated at $15-20M annually.
- Price per cycle remains high at approximately $2,680, with potential increases driven by market expansion and regulatory developments.
- Off-label use of older drugs like 3,4-DAP creates indirect competition but does not currently threaten the FDA-approved product’s market share significantly.
- Market growth depends on disease diagnosis rates, regulatory reforms, and patent or exclusivity periods.
- Future pricing could fall post-2024 due to the introduction of generics or biosimilars, assuming market entry.
FAQs
1. What is the main driver behind the current high price of Ruzurgi?
The price reflects the limited patient population, FDA approval for a rare disease, and market exclusivity that prevents generic competition until 2024.
2. How do off-label treatments impact Ruzurgi's market?
Off-label use of older drugs like 3,4-DAP provides an alternative but is less predictable and not FDA-approved, which limits direct competition but can influence prescribing behavior.
3. Are there regulatory plans that could change the pricing landscape?
Potential approval of expanded indications or biosimilar entry post-2024 could reduce costs.
4. What factors could accelerate market growth for NDC 49884-0306?
Broader diagnosis of LEMS, increased clinician awareness, and insurance coverage expansion may enhance sales.
5. What is the long-term outlook for Ruzurgi's pricing?
Prices are likely to remain stable until patent or exclusivity ends, after which competition will probably lead to a decline.
Sources:
[1] FDA drug database, April 2023.
[2] IQVIA sales estimates for rare disease therapeutics, 2022.
[3] Market research reports on rare disease drugs, 2023.
[4] Price analysis reports, Medicaid and private insurer reimbursements, 2023.
[5] Lambert-Eaton Myasthenic Syndrome prevalence data, University of Rochester, 2021.
